The Bourne Report Summary

Well it was an interview that was about 45 minutes long and primarily discussed the bio-reactor at Welches and the prospects going forward.

As far was Welches is concerned, they are going ahead with the new facility and after it is built it is up to Welches to determine if they want to roll it out at other plants (Welches has four juice plants in the U.S.). When will this start? Well, apparently there is a bit of snow up there and it will be a little while before they can dig out and get going. But don't despair it does not sound like it will be too long.

With the comercial facility Welches will be able to generate power for thier own use or feed it back into the grid and effectively sell it back to their utility provider in order to reduce their utility bills.

The technology is definitely scalable on the upside but Bret does not see it being scaled down for use at home.

In regards to getting off the pink sheets, Bret did say that work is bing down to move to an OTC listing but was not committing to any time frame.

The medical testing got some play at the very end. He described how it works and that it is already being manufactured and he expects to be promoting and marketing this more.

All in all, nothing earthshattering but there continues to be a consistent message.

Grants and Contracts Coming Soon

Here is my synopsis of the interview:

Welch’s
-Prototype plant used waste water with 0.3% sugar. This produced 1L of Hydrogen for each gallon of waste water
-They are now going to start testing waste water with 16% sugar. They expect to yield up to 50L of hydrogen from each gallon of waste water
-Welch’s commercialization is anticipated to start in the first half of 2008 to replace the current prototype (once winter weather breaks and allows construction to begin). Nanologix does not anticipate funding this venture. It is hoped it will be funded by Welch’s and by State and Federal grants.

Grants
-Nanologix has hired a grants specialist. It is expected that grants will be achieved by Q2 2008. This date coincides with State and Federal Budgeting for various grants that Nanologix is working on. If Nanologix is successful in obtaining grants from various state (Ohio and Pennsylvania) and federal sources it will be by the end of 2008.

Testing Kits
-Nanologix also met with the Department of Defense in July. Currently if there is an outbreak where bacteria (such as Anthrax) is suspected, it takes seven days to test for bacterias in a contaminated building using petri dish technology. Using the Bionanochannel technology developed by Nanologix it takes only 7 hours. The Department of Defense was quite excited by this. Nanologix expect a contract in the near future with the Department of Defense and hope to come to an agreement soon.

Erie Wastewater
- Nanologix is also working on developing a prototype for sludge wastewater at the Erie wastewater treatment plant as.

Share Value
-Current market value does not reflect true value as Nanologix is off the radar screens of most investors. Mr. Barnhizer believes that will change rapidly once contracts are announced and investor awareness increases.

EOM

Hum,

In all likelyhood, people will look at the flyer, crumple it up and carry on. However, someone may look at it and send it to a securities regulator or similar such law enforcement authority.

The issue with spam is not in the medium employed to get the message out. It could be email, it could be door-to-door, it could be carrier pigeon for that matter. The issue is to do with stock manipulation. Whether or not such a campaign is employed by the company is immaterial. YOU are a shareholder, which means that anything you do to promote the company through mass communication could be scrutinized. What securities regulators are looking for are people pumping up worthless companies in order to profit quickly. The classic pump and dump scenario.

I have no doubt that your intentions are noble and are not connected to any such campaign. But in life perception is reality. If NNLX is being promoted via the internet, door-ro-door flyers or otherwise in an unsolicited manner with information not approved by the company -- it looks bad. It makes the company look like just another one of those spam emailers. NOT what we want NNLX associated with.

So what to do? Obviously you care about the environment (I am ignoring the trees you would kill with your flyers Ha Ha) and you care about making money off this stock. The two do not have to be mutually exclusive. Call up NNLX. Talk to the senior management. Tell them you are a shareholder and want to help promote the company. If they take you up on your offer you will be able to provide much needed PR with the blessing and approval of the company. I am sure that NNLX would only approve such promotional campaigns with the focus of portraying NNLX is the best light possible. This may include a posting on Wikipedia as someone mentioned. It may involve workign with the NNLX team in order to help represent them at trade shows. there are many such possibilies.

NNLX may also not take you up on your offer. They may have other PR plans in place. They may deem your experience (other than being an enthusiastic shareholder) to be insufficient. They may just want to focus on cleanign up their financials and not on PR until that is done. But whatever the reason if they say no then you have to just go with the flow and understand that as a minority shareholder of a public company you cannot exercise any control over the company other than what your percentage of shares allows you to control.

So to summarize:
Unauthorized promotion - Bad
Working with NNLX if they want the help -- Good

Mr. Moe

Low Tech NNLX Spamming?

You guys can't be serious about going door-to-door with flyers promoting NNLX. Given that NNLX is in the process of cleaning up its financials in order to get off the Pinks I can't see this as being a big help. Any Pink sheet company that is part of an email spam campaign is automatically put under intense scrutiny by regulatory bodies. In fact the new system of pink sheet issuer classifications specifically mentions this type of activity. The classifications are as follows:

1. Current Information - Indicates reporting companies that submit filings to regulators with powers of review and that make the filings publicly available or non-reporting companies that make current information publicly available on the Pink Sheets News Service.

2. Limited Information - Is designed for companies with financial reporting problems, economic distress, or in bankruptcy to make the limited information they have publicly available.

3. No Information - Indicates companies that are not able or willing to provide disclosure to the public markets - either to a regulator, an exchange or Pink Sheets.

4. Caveat Emptor - Buyer Beware. There is a public interest concern associated with the company, which may include a spam campaign, stock promotion or known investigation of fraudulent activity committed by the company or insiders. During a spam campaign, any stock that is not in the Current Information category will also have its quotes blocked on pinksheets.com.

Currently NNLX is at Level Three -- No Information. Management has indicated that they are in the process of trying to move off the pinks which entails financial disclosure to the standard of Level One. I am sure they would not be at all happy if a spam campaign or a door to door flyer campaign landed them in Level Four.

So please, do not engage in such an activity. If you want to get the word out about NNLX, talk to your friends, talk to your family, talk to your broker but do not engage in unregulated, unsanctioned promotional activities that will be detremental to all NNLX shareholders.

Moe

Having looked for a Penwest Renewable Energy Conference I found the following:

1. Nothing relating Penwest to a Renewable energy conference
2. Penwest is a Pharmaceutical company - why would they host a renewable energy conference?
3. It is likely that the conference referred to in the PR is the Power-Gen Renewable Energy 2007 Conference held at the Mandalay Bay Resort in Las Vegas from Mach 6 - 8th. The conference is run by a company called PenWell.

http://pgre07.events.pennnet.com/fl/home.cfm?Language=

If this is the case NNLX should re-release the PR with the correct info.

Having looked for a Penwest Renewable Energy Conference I found the following:

1. Nothing relating Penwest to a Renewable energy conference
2. Penwest is a Pharmaceutical company - why would they host a renewable energy conference?
3. It is likely that the conference referred to in the PR is the Power-Gen Renewable Energy 2007 Conference held at the Mandalay Bay Resort in Las Vegas from Mach 6 - 8th. The conference is run by a company called PenWell.

http://pgre07.events.pennnet.com/fl/home.cfm?Language=

If this is the case NNLX should re-release the PR with the correct info.

Press Release on NNLX @ Renewable Energy Conference

Press Release Source: NanoLogix


NanoLogix Presents Hydrogen Production Technologies at Penwest Renewable Energy Convention in Las Vegas
Wednesday March 7, 2:23 pm ET


SHARON, PA--(MARKET WIRE)--Mar 7, 2007 -- NanoLogix, Inc. (Other OTC:NNLX.PK - News) is pleased to announce its participation at the Penwest Renewable Energy Conference in Las Vegas on March 7 and 8.


Dana Allen, Member of the Board of Directors and VP of Strategic Partnering, representing NanoLogix at the convention, stated, "This is a premier event in the industry with attendance in the thousands. The attendance this year is approximately double last year's, all of which indicates the explosive growth in this industry. We are discussing the advantages of generating Hydrogen from biomass and biowaste using NanoLogix patented technologies, instead of using the traditional energy wasting methods requiring natural gas or electrical power." Mr. Allen may be contacted at the event by calling 650-743-7111 .

NanoLogix will be presenting at The National Hydrogen Conference in Houston in April. Dr. Harry Diz will be presenting a scientific paper, Paper #3306 "Microbial Production of Hydrogen from Sugar-rich Wastewater," at the conference regarding the NanoLogix Hydrogen Bioreactor currently operating at the Welch Foods plant in Pennsylvania. Additional information regarding booth and presentation times will be issued prior to the conference.

Dr. Diz's scientific paper regarding the NanoLogix hydrogen test site at Welch's concluded with the following excerpt, "Hydrogen production was sustained over more than six months of operation while methane production was controlled and limited. This experience confirmed the ability to maintain a hydrogen-generating culture in an industrial setting over an extended period of time."

About NanoLogix, Inc.:

NanoLogix is an industry innovator in the research, development and commercialization of nano-biotechnologies, applications and processes. The Company owns or has the rights to 32 patented technologies. The Company is currently focused on the production of hydrogen from agricultural feedstock, industrial wastewater and municipal waste streams to create new sources of energy. NanoLogix is presently operating a hydrogen bioreactor at Welch's Food and has recently signed an agreement with the City of Erie Wastewater Treatment Plant for a prototype bioreactor installation. Additionally, NanoLogix develops and markets diagnostic test kits for use in early detection of infectious human diseases such as cancer, cystic fibrosis and AIDS, and owns a patent for the non-toxic induction of apoptosis ('cell suicide') for the treatment of cancer. For more information on the Company, visit http://www.nanologix.net.

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.



Contact:
Contacts:
Investor Relations
Andrew Barwicki
516.662.9461

Website: http://www.nanologix.net

One and the same.

NanoLogix Initiates Activities to Attain Fully Reporting Status
SHARON, Pa., Jan 18, 2006 (BUSINESS WIRE)
NanoLogix, Inc. (Pink Sheets:NNLX) today announced that the company will retain the services of a PCAOB registered accounting firm. It is the Company's intent to become a reporting entity on the NASD Bulletin Board exchange. Once the auditors have completed the necessary audits the company's legal counsel the law firm of Randall S. Goulding & Associates will prepare and file a 10-SB with the SEC with the intent of switching exchanges.

CEO of NanoLogix Dr. Mitch Felder commented, "Considering our short history and modest capital resources, our accomplishments have been nothing short of spectacular. We always believed that as soon as the cornerstones of real potential economic value were in place, namely NanoLogix's patent portfolio, and our ongoing capital needs had been secured, it would be necessary to take the next steps in terms of complete transparency and public disclosure in order to reward our existing shareholders and attract new ones." Dr. Felder continued, "The retention of the appropriate professionals, as well as the recent additions to our Board, is another major step for NanoLogix in its growth plan."

As previously announced, NanoLogix has added David F. Rivers to its Board of Directors. Mr. Rivers was with Pfizer (NYSE:PFE) for 34 years. He was Vice President in charge of the Research, Development, and Engineering operations for the Schick & Wilkinson Sword Group since 1993. In this position he was responsible for all new product and process activity for the business worldwide. Mr. Rivers worked in the Fisher Body Division of General Motors (NYSE:GM) in Engineering, Quality, and Manufacturing operations before joining Pfizer. He began his career at Pfizer in 1969 as a Production Superintendent in the Schick Operations and held increasingly responsible positions in the Schick and Consumer Products groups in both Manufacturing, Engineering and Research and Development. He retired from Pfizer in October 2003 to become CEO of the Patriot Lift Company. Patriot Lift Company (http://www.patriotlift.com) manufactures and sells the exclusive technology for Pneumatic automation of landing gear and stabilizers for the Trucking Industry.

Randall Goulding, NanoLogix corporate counsel, stated, "From the outset of our relationship with the company we recognized not only the potential for NanoLogix's economic successes but also the benefit the Company's products could have on society at large. It was a combination of the two that compelled us to conserve the company's cash position and instead be retained solely for restricted stock." He continued, "There is an inherent global socio-economic benefit that is at stake here. The fact that such a small Company could create market-leading disease detection capabilities while developing a technology capable of generating a high-grade of clean burning fuel from waste products is truly amazing. Their endorsement by a major company like Welch's(R) demands recognition and, as citizens of the world, their achievements demanded our call-to-action. We are honored to be assisting the Company take this next critical step in its growth."

About NanoLogix, Inc.

NanoLogix is a nanobiotechnology company that engages in the research, development, and commercialization of technologies for the production of bacteria, disease testing kits, alternative sources of fuel, cancer therapy, and remediation of toxic materials. The Company's patents span the identification and antibiotic sensitivity testing of 34 disease-producing bacteria, including M. tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS. Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis (a method for inducing a genetically based induction of "cell suicide") in cancer cells utilizing hydrophobic hydrocarbons. NanoLogix is currently implementing a technology application for biogas products and services designed to assist in worldwide energy independence and reduce pollution from renewable, environmentally-friendly energy sources.

Forward-Looking Statements

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

FOR FURTHER INFORMATION, go to the Company's website at: http://www.NanoLogix.net

SOURCE: NanoLogix, Inc.

For NanoLogix, Inc., Sharon Brass Bulls Corp. Matthew Lovito, 866-342-2700

Copyright Business Wire 2006

Business Wire via Comtex via Comtex. Copyright 2006 Powered By Stockgroup

I think we have been chewing through them for the past eight months.

I am shocked! Utterly Shocked. I can't believe that OTC Financial would have a favorable profile of Nanologix. I mean Nanologix only hired them three weeks ago. I guess offering a negative review would have jeopardized their long term consulting relationship.

But seriously, who can take this seriously? I mean if they paid me $90,000 I would write that NNLX is going to be the second coming of Microsoft.

Instead of hiring a consulting firm to say nice things about NNLX, perhaps NNLX should focus on business at hand.

Moe


OTC Financial Network Issues Favorable Corporate Profile on NanoLogix
SHARON, Pa., Aug. 15 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX), a nano-biotechnology company engaged in the development and commercialization of technologies for the creation of hydrogen bioreactors, today announced that OTC Financial Network, a division of National Financial Communications Corp. and the nation's leading micro/small-cap investor relations firm, issued a favorable InvestorFacts report on NanoLogix. The report highlights NanoLogix's technological advantages, market opportunities, growth strategies and management team. To read the report online, visit http://otcfn.com/nnlx/report.html or call 781-444-6100 for reprints.

Geoffrey J. Eiten, publisher of OTC InvestorFacts, stated, 'NanoLogix's current hotbed of opportunity is in commercializing its proprietary and patented hydrogen bioreactor process to create alternative energy sources from industrial and municipal waste streams. As consumers continue to feel the affects of skyrocketing oil and gas prices, finding alternative renewable sources of energy remains a national priority. The generation of hydrogen demonstrates NanoLogix' capability to convert its prolific intellectual property portfolio into much needed alternative energy sources.'

Eiten continued, 'NanoLogix has assembled a stellar leadership team that lends long-standing strategic and international business relationships to better the Company's competitive and marketing position. The Company is targeting thousands of potential new clients, primarily municipalities, multinational energy concerns and those in the industrial sector, providing investors a ground floor opportunity to maximize returns over the long-term.'

About OTC Financial Network

Since 1992, OTC Financial Network has provided consulting services and customized, proactive investor relations campaigns to more than 500 small/micro-cap public companies. OTC Financial Network designs and implements results-driven direct mail, electronic marketing, shareholder communications and other programs to increase market awareness on behalf of its clients. A partnership with OTC Financial Network can improve a company's shareholder communications channel, facilitate capital formation opportunities, create an expanding and diversified base of institutional and retail shareholders, and garner financial media coverage. OTC Financial Network is a division of National Financial Communications Corp. based in Needham, MA. For more information visit http://www.otcfn.com/ and http://www.nationalfc.com.

About NanoLogix, Inc.

NanoLogix is an industry innovator in the research, development and commercialization of nano-biotechnologies, applications and processes. The Company owns or has the rights to an extensive portfolio of 32 patented technologies and 22 more applications are pending. The Company is currently focused on the production of hydrogen from agricultural feedstock, industrial wastewater and municipal waste streams to create new sources of energy. NanoLogix is successfully operating a hydrogen bioreactor at Welch's Food and has recently signed an agreement with the City of Erie Wastewater Treatment Plant for a prototype bioreactor installation. Additionally, NanoLogix develops and markets diagnostic test kits for use in early detection of infectious human diseases such as cancer, cystic fibrosis and AIDS, and owns a patent for the non-toxic induction of apoptosis ('cell suicide') for the treatment of cancer. For more information on the Company, visit http://www.nanologix.net.

Disclaimer: OTC Financial Network, a division of National Financial Communications Corp., serves as special advisor to NanoLogix, Inc. and has received fees for services, in the amount of ninety thousand dollars for one year of service, payable in restricted shares plus an option to purchase an aggregate of five hundred thousand shares of restricted common stock at an exercise price of forty cents per share, plus expenses, for the creation and distribution of materials, including the InvestorFacts report. This is not an offer to buy or sell securities. Information or opinions in this release are presented solely for informative purposes, and are not intended nor should they be construed as investment advice. Additional compensation information and a full disclaimer can be found online by visiting http://www.otcfn.com/nnlx and selecting the 'Disclaimer' link.

This press release contains statements, which may constitute 'forward- looking statements' within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.


Contact:
At OTC Financial Network
Geoffrey Eiten
Investor Relations
781-444-6100x613
geiten@otcfn.com
www.otcfn.com/nnlx

SOURCE NanoLogix, Inc.


Source: PR Newswire (August 15, 2006 - 9:29 AM EDT)

News by QuoteMedia
www.quotemedia.com

http://www.tngroupllc.com

Assuming a stock price of approx. 5 cents at the time, Nutmeg could have recieved 15 million shares in return for the $750,000. I assume they have been leaking them out ever since.

NanoLogix Receives Financing Commitment and Strategic Assistance From U.S. Investment Fund


Thursday, January 12, 2006

SHARON, Pa., Jan. 12 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (Pink Sheets: NNLX) today announced that it has received a financing commitment fostered by The Nutmeg Group, a prominent U.S.-based investment fund. The initial commitment totaling $750,000 will enable the Company to reach critical milestones in the roll-out of its hydrogen generation system technologies to be deployed at Welch's as well as the commercialization of its medical diagnostic products.

Randall S. Goulding, Managing Director of The Nutmeg Group, stated, "We believe that the Company's current valuation is not at all reflective of its existing intrinsic value or its near and long-term prospects, particularly with respect to its technology deployment at Welch's. The Company's talented management, unique offerings and their potential for exponential expansion has prompted both our ongoing financial and strategic commitment." He continued, "The initial capital infusion will be allocated towards operational ramp-up in order to seize existing revenue opportunities as well as the exploration of new business opportunities and joint ventures, several of which are already in the works."

With more than 30 million dollars under management, The Nutmeg Group is a value-added private capital investment firm and a full service investment and financial consulting organization, dedicated to helping growth companies emerge as industry leaders. Staffed with an impressive array of diverse talents and a robust infrastructure, Nutmeg stands committed to facilitating NanoLogix's success, as it is for all of its portfolio companies. Loren Comitor, President of CCM&A, Nutmeg's advertising and marketing affiliate, will facilitate new global marketing arrangements for NanoLogix as well as enhance the Company's image and aesthetic so that they are commercially friendly and reflective of the Company's outstanding prospects.

David C. McClelland, President of NanoLogix, commented, "We are extremely please to have the Nutmeg Group playing a vital role in NanoLogix's future. While their initial financial commitment enables the Company to reach some critical milestones, it is the intangible value of both their collective strategic expertise and deep global business relationships that makes this partnership a 'no-brainer.'"

About NanoLogix, Inc.

NanoLogix is a nanobiotechnology company that engages in the research, development, and commercialization of technologies for the production of bacteria, disease testing kits, alternative sources of fuel, cancer therapy, and remediation of toxic materials. The Company's patents span the identification and antibiotic sensitivity testing of 34 disease-producing bacteria, including M. tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS. Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis (a method for inducing a genetically based induction of "cell suicide") in cancer cells utilizing hydrophobic hydrocarbons. NanoLogix is currently implementing a technology application for biogas products and services designed to assist in worldwide energy independence and reduce pollution from renewable, environmentally-friendly energy sources.

Forward-Looking Statements

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

SOURCE NanoLogix, Inc.

For further information: Brass Bulls Corp., +1-866-342-2700, for NanoLogix, Inc.

© PR Newswire

Nutmeg has to be the one selling. They got in at a ridiculously low price and have been selling all the way up and down.

Almost six weeks since last news . . . hmmm

So basically you need a market maker to file a Form 211. The NASD checks to see if you are compliant. If the company has not been filing they can complete the 10-SB to bring the company up to the required filing status.

The 10-Sb can take 60 days before the NASD responds, at which point it may have to be refiled with changes. The Form 211 time period is not determined so OTC BB status depends on how many questions there are and how well the 10-SB was executed.

The procedures followed by The OTCBB Filings Department for determining a company’s compliance status with respect to the Eligibility Rule are as follows:


Determine Compliance - To be compliant with the Eligibility Rule, a company must be:
Registered with the SEC under Section 13 or 15(d) of the Securities and Exchange Act of 1934 ("Act"), an investment company registered under the Investment Company Act, an insurance company described in Section 12(g)(2)(G) of the Act, or a bank or savings association that is not required to file reports with the SEC.
AND


Current in its required filings. To be current, an issuer must have filed its latest required annual filing and any subsequent quarterly filings. In the alternative, an issuer may be deemed compliant if it has filed a Form 10 or a Form 10SB and has cleared all comments by the SEC.

After a Form 211 is filed, how long until the security can begin quotation on the OTCBB?
There is no standard time to process a 211 and clear the market maker to begin quoting a security on the OTCBB. The time it takes to review a 211 may vary significantly depending on many factors including whether or not NASD has to request additional information from the market maker that submitted the form and upon how long it takes the market maker to respond to requests for additional information.

Form 211

http://www.otcbb.com/AboutOTCBB/forms/form211.pdf

How To Quote Securities

Market Maker Benefits

Participating Market Makers may:


register in as many securities as desired;
update bid and ask quotations on a real-time basis for domestic securities, foreign securities and ADRs and make twice daily quote updates for DPPs;
enter one-sided or two-sided quotes;
attract bids through "offer-wanted" (OW) entries and offers through "bid-wanted" (BW) entries; and
advertise an unsolicited interest in a particular security without specifying a price.

Registering to Make Markets in OTCBB Securities

The OTCBB operates as a dealer system. As a result, all securities being quoted on the OTCBB must be sponsored by a participating Market Maker that registers the security by completing a Form 211 unless an exemption applies. The Market Maker must submit a Form 211 to the NASD OTC Compliance Unit along with two copies of the required issuer information no less than three business days prior to publication of a quote on the OTC Bulletin Board. Once cleared, Nasdaq Market Data Integrity will notify the Market Maker that it has been registered in the security and may enter a quote.

Ineligible Securities
Every OTC security not currently quoted on the OTC Bulletin Board is considered "ineligible" until a Market Maker submits a Form 211 or a 15c2-11 Exemption Form. After clearance, the security is granted "eligible" status.

Eligible Securities
If a security has eligible status, it means one or more Market Makers has received clearance to quote the issue on the OTC Bulletin Board within the last 30 days. Any other participating Market Maker that wishes to quote the issue must also submit a completed Form 211. During the "eligible" period, a frequency-of-quotation test is administered. The test is described below. Until the test is satisfied, all Market Makers must continue to submit a completed Form 211.

Active Securities
An OTCBB-eligible security that meets the frequency-of-quotation requirement for the so-called "piggyback" exception is identified in the service as "active." The frequency-of-quotation test or "piggyback" exception is based on whether a broker/dealer has itself published quotations in the security in the applicable interdealer quotation system on at least 12 business days during the preceding 30 calendar days, with not more than four consecutive business days without quotations. Once this criteria has been satisfied, authorized participants may register on-line in a security. As long as the security remains in an "active" state, any participant may quote the security without a Form 211 submission.


Other Exemptions to 15c2-11

Before an issue can be quoted on the OTC Bulletin Board® (OTCBB), a Market Maker must first determine if it is already listed on a U.S. national exchange or market. If the issue is listed on a national exchange or market, it may not be quoted on the OTCBB. Market Makers should also check to see if the issue is on the National Quotation Bureau's Pink Sheets. If it is on the Pink Sheets, then, to quote on the OTCBB, the Market Maker quoting the issue may file an exemption to the 15c2-11 rather than a full Form 211; non-Market Makers must file a Form 211.

If the issue is listed on a regional exchange:
If the issue is listed on a regional exchange, is current in its SEC filings, and does not meet the minimum criteria for inclusion in the Consolidated Quotation and Transaction Reporting Systems, a Rule 15c2-11 Regional Security Exemption Form should be filed for quotation on the OTCBB. If the issue does not meet the exemption criteria, a full Form 211 must be filed for quotation on the OTCBB.

If the issue has been delisted from Nasdaq:
If the issue has been delisted from The Nasdaq Stock MarketSM because it has not maintained Nasdaq's listing requirements and the security meets the following criteria, then the issue will be available for immediate quotation on the OTCBB only for those Market Makers quoting in the security during the 30-day period preceding its removal.

The security has been quoted continuously on Nasdaq® during the 30 calendar days preceding its delisting, exclusive of any trading halt not exceeding one day to permit the dissemination of material news concerning the security's issuer.
The issuer must not be the subject of bankruptcy proceedings.
The issuer must be current in its filings.
If the issue does not meet all of the above criteria upon delisting, a Form 211 must be filed for quotation on the OTCBB.

The Form 211 must be completed and mailed with two copies of the required issuer information to NASD Regulation, Inc. at the following address:

NASD Regulation, Inc.
OTC Compliance Unit
9509 Key West Avenue
Rockville, MD 20850
phone: (240) 386-5100
fax: (240) 386-5139


The OTC Compliance Unit will review the information and contact applicants if additional information is necessary. A notification will be sent out when the application has been cleared.

SHARON, Pa. (AP) _ NanoLogix Inc. said hydrogen has been generated at its first commercial scaled-up hydrogen bioreactor facility.


The reactor is at a Welch Food's plant in North East and generates hydrogen from waste organic matter.


The technology behind NanoLogix's bioreactor is intended to enable manufacturing facilities to convert their waste stream into hydrogen.


The alternative energy source then can be converted, on-site, to electricity, thus contributing immediately to the manufacturing facilities' bottom line.

www.otc-advisors.com: "Bulls in the Stable" IKMA, GSPG, ADVR, NNLX, GZPN

Rochester, NY, May 10, 2006 (M2 PRESSWIRE via COMTEX) -- www.otc-advisors.com names iKarma, Inc. (Pink Sheets: IKMA), GoldSpring, Inc. (OTCBB: GSPG), Advanced Viral Research Corporation (OTCBB: ADVR), NanoLogix, Inc. (Pink Sheets: NNLX) and GreenZap, Inc. (Pink Sheets: GZPN ) its "Bulls in the stable."

NanoLogix, Inc. (Pink Sheets: NNLX - http://finance.yahoo.com/q?s=NNLX.PK)

NanoLogix, Inc. (Pink Sheets: NNLX) announced today that hydrogen has been generated at its first commercial scaled-up hydrogen bioreactor facility at a Welch Food's plant in North East, Pennsylvania. The company previously announced the construction of the facility and its intent to begin hydrogen generation from Welch's waste organic matter.

The dependence upon fossil fuels is drawing to a close with the achievement of alternative fuel from waste streams from manufacturing facilities worldwide.

The technology behind the hydrogen bioreactor, developed and proprietary to NanoLogix, is intended to enable manufacturing facilities to convert their waste stream into hydrogen. The alternative energy source then can be converted, on-site, to electricity, thus contributing immediately to the manufacturing facilities bottom line.

David F. Rivers, a director of NanoLogix, CEO of Patriot Lift Company (http://www.patriotlift.com) and who spent more than 30 years with Pfizer's Schick & Wilkinson Sword business unit and General Motors' Fisher Body Division in Senior Research, Development and Engineering operations, commented that, "The generation of hydrogen demonstrates NanoLogix's capability to convert its prolific intellectual property portfolio into needed technologies."

David C. McClelland, President of NanoLogix, commented, "The success NanoLogix has had in converting the waste stream at Welch's into hydrogen is indicative of the extremely exciting possibilities for continuous generation of hydrogen in the future."

Professor Rick Diz of Gannon University, the lead scientist in the project and consultant to NanoLogix stated, "I am pleased to confirm the bioreactor at Welch's is producing hydrogen. Gas chromatography confirmed hydrogen and no methane."

About NanoLogix, Inc.

NanoLogix is a nano-biotechnology company whose extensive portfolio of patents have application and marketability in the following areas: nanoscale microfluidics for the rapid identification of disease causing pathogens utilizing BioMEMS; production of high value hydrogen from agricultural feedstock, industrial waste water and municipal waste streams; nontoxic induction of apoptosis (a method for inducing a genetically based induction of "cell suicide") in cancer cells utilizing hydrophobic hydrocarbons; and the bio-remediation of air, water and soils of harmful contaminants.

I like the last paragraph here.


COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:

bellwetherreport.com: The Bellwether Report Issues an Agressive Investors Alert for NanoLogix, Inc

May 11, 2006 (M2 PRESSWIRE via COMTEX) -- NanoLogix, Inc (OTCBB:NNLX), is a company that our research team will be tracking over the ensuing weeks. They recently came out with a significant corporate development, causing a market stir. The BWR Research Team will continue to bring its subscribers cutting edge research tools, and second to none customer service.
NanoLogix, Inc, a nano-biotechnology company whose extensive portfolio of patents have application and marketability, this morning announced that hydrogen has been generated at its first commercial scaled-up hydrogen bioreactor facility at a Welch Food's plant in North East, Pennsylvania.

The dependence upon fossil fuels is drawing to a close with the achievement of alternative fuel from waste streams from manufacturing facilities worldwide.

The technology behind the hydrogen bioreactor, developed and proprietary to NanoLogix, is intended to enable manufacturing facilities to convert their waste stream into hydrogen. The alternative energy source then can be converted, on-site, to electricity, thus contributing immediately to the manufacturing facilities bottom line.

David F. Rivers, a director of NanoLogix, CEO of Patriot Lift Company and who spent more than 30 years with Pfizer's Schick & Wilkinson Sword business unit and General Motors' Fisher Body Division in Senior Research, Development and Engineering operations, commented that, "The generation of hydrogen demonstrates NanoLogix's capability to convert its prolific intellectual property portfolio into needed technologies."

David C. McClelland, President of NanoLogix, commented, "The success NanoLogix has had in converting the waste stream at Welch's into hydrogen is indicative of the extremely exciting possibilities for continuous generation of hydrogen in the future."

Professor Rick Diz of Gannon University, the lead scientist in the project and consultant to NanoLogix stated, "I am pleased to confirm the bioreactor at Welch's is producing hydrogen. Gas chromatography confirmed hydrogen and no methane."

Following this announcement NanoLogix, Inc traded very quickly this morning as investors jumped in driving this company up $0.06 to reach as high as $0.37. But since then this company has taken a bit of a pull-back as investors sell off shares taking in their profits. This company has an unbelievable technology and I feel is to good to pass up. NanoLogix should have a heck of a life time as energy costs continue to rise, a need for alternative fuels is an all time high. The BWR Research Team will continue to follow the market sentiment on this company and numerous others.

Some details on the hydrogen production. (Professor Diz is the lead on the NNLX project).

Gannon University
Environmental Science & Engineering
Research Activities

Hydrogen Gas Production from Food Processing Wastewater

Professor Diz, undergraduate students Matt Drury, Buck Neely, Ross Hollenbeck, Wes Willow

It has been known by microbiologist for decades that many microorganisms produce hydrogen gas as a normal part of their metabolism. Normally, the hydrogen produced is immediately converted to other products such as methane by other bacteria. As a result, bacterial production of hydrogen has not yet been shown to be a practical method to produce this valuable gas.

This project is developing the technology necessary to avoid conversion to methane. Thus far, anaerobic bioreactors in the laboratory have been producing hydrogen gas for more than ten months without any methane generation. Factors to optimize the system design are now being studied, and a pilot-scale system is planned for the near future at a food processing factory on the outskirts of Erie.

told you NNLX news comes out in the morning!

NanoLogix Announces the Successful Conversion of Welch's Waste Stream into Usable Hydrogen


SHARON, Pa., May 10 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (Pink
Sheets: NNLX) announced today that hydrogen has been generated at its first
commercial scaled-up hydrogen bioreactor facility at a Welch Food's plant
in North East, Pennsylvania. The company previously announced the
construction of the facility and its intent to begin hydrogen generation
from Welch's waste organic matter.
The dependence upon fossil fuels is drawing to a close with the
achievement of alternative fuel from waste streams from manufacturing
facilities worldwide.
The technology behind the hydrogen bioreactor, developed and
proprietary to NanoLogix, is intended to enable manufacturing facilities to
convert their waste stream into hydrogen. The alternative energy source
then can be converted, on-site, to electricity, thus contributing
immediately to the manufacturing facilities bottom line.
David F. Rivers, a director of NanoLogix, CEO of Patriot Lift Company
(http://www.patriotlift.com) and who spent more than 30 years with Pfizer's
Schick & Wilkinson Sword business unit and General Motors' Fisher Body
Division in Senior Research, Development and Engineering operations,
commented that, "The generation of hydrogen demonstrates NanoLogix's
capability to convert its prolific intellectual property portfolio into
needed technologies."
David C. McClelland, President of NanoLogix, commented, "The success
NanoLogix has had in converting the waste stream at Welch's into hydrogen
is indicative of the extremely exciting possibilities for continuous
generation of hydrogen in the future."
Professor Rick Diz of Gannon University, the lead scientist in the
project and consultant to NanoLogix stated, "I am pleased to confirm the
bioreactor at Welch's is producing hydrogen. Gas chromatography confirmed
hydrogen and no methane."
About NanoLogix, Inc.
NanoLogix is a nano-biotechnology company whose extensive portfolio of
patents have application and marketability in the following areas:
nanoscale microfluidics for the rapid identification of disease causing
pathogens utilizing BioMEMS; production of high value hydrogen from
agricultural feedstock, industrial waste water and municipal waste streams;
nontoxic induction of apoptosis (a method for inducing a genetically based
induction of "cell suicide") in cancer cells utilizing hydrophobic
hydrocarbons; and the bio-remediation of air, water and soils of harmful
contaminants.
Forward-Looking Statements
This press release contains statements, which may constitute "forward-
looking statements" within the meaning of the Securities Act of 1933 and
the Securities Exchange Act of 1934, as amended by the Private Securities
Litigation Reform Act of 1995. Those statements include statements
regarding the intent, belief or current expectations of Nanologix, Inc.,
and members of its management as well as the assumptions on which such
statements are based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance and
involve risks and uncertainties, and that actual results may differ
materially from those contemplated by such forward-looking statements. The
Company undertakes no obligation to update or revise forward-looking
statements to reflect changed assumptions, the occurrence of unanticipated
events or changes to future operating results.



SOURCE NanoLogix, Inc.

.305 - .32 before the open.

I was just observing that all NNLX news seems to come out in the morning . . . except the last PR about hiring the energy guy.

Soooo I was just musing that perhaps the strength of NNLX today was based on some pending news.

NNLX usually puts news out in the morning but their last news actually came out just after the market closed. could it be the long anticipated Welch's results? or perhaps a JV or licensing announcement?

NNLX forecast from Stocktargets.com



USERS CONSENSUS FORECAST FOR NNLX.PK Target Expected Return Change Over 1 Week
Last Close: 0.27
1 week: 0.47 74% 0.03
1 month: 0.59 118.5% 0.04
3 months: 0.88 225.9% 0.03
6 months: 1.26 366.6% -0.01
12 months: 2.4 788.8% 0.06

PROFESSIONAL ANALYSTS, BROKERS AND FUND
MANAGERS FORECAST FOR NNLX.PK
Enter your Pro Targets Company Target Horizon Upside Recommendation Date
Avge Pro Target 0.92 12 Months 240.7%
TTS Zurich 0.92 12 Months 240.7% Buy 03/30/06

Hmmm, good volume. Price moving. Something is up.

Open at .28

Bid .265 Ask .27 at the open.

This is definitely a good sign. It shows that the company is starting to ramp up for the distribution of its technology. By looking to partner with the existing energy establishment they will co-op them as opposed to competing against them. Smart.

NanoLogix Announces the Addition of Energy Specialist to Hydrogen Bioreactor Project
5:04 PM EDT May 3, 2006
NanoLogix, Inc. (Pink Sheets: NNLX) announced today that it has secured the services of Bret T. Barnhizer to assist the Company in marketing their biomass-to-hydrogen technology to the energy industry. Mr. Barnhizer brings extensive experience and expertise in the United States and worldwide energy industry to NanoLogix, having worked for the last twenty-six years providing engineering, operations management, and project management services to Chevron, BP, Unocal, Occidental Petroleum, and others in the United States, Europe, Africa, and Asia. Mr. Barnhizer is an alumnus of Youngstown State University and the University of Colorado at Boulder, with areas of specialization in International Relations and Environmental Studies.

David F. Rivers, a director of NanoLogix, CEO of Patriot Lift Company (http://www.patriotlift.com) who spent more than 30 years with Pfizer's Schick & Wilkinson Sword business unit and General Motors' Fisher Body Division in Senior Research, Development and Engineering operations, commented that, "The addition of such a distinguished energy industry figure to the NanoLogix team will greatly enhance the company's relationship with numerous multinational corporations."

Mitchell S. Felder, M.D., the CEO of NanoLogix added, "I have been incredibly impressed with Mr. Barnhizer's knowledge and contacts within the energy sector. I believe that his assistance to the company will greatly accelerate this exciting endeavor which has the potential to change the worldwide energy paradigm."

About NanoLogix, Inc.

NanoLogix is a nano-biotechnology company whose extensive portfolio of patents have application and marketability in the following areas: nanoscale microfluidics for the rapid identification of disease causing pathogens utilizing BioMEMS; production of high value hydrogen from agricultural feedstock, industrial waste water and municipal waste streams; nontoxic induction of apoptosis (a method for inducing a genetically based induction of "cell suicide") in cancer cells utilizing hydrophobic hydrocarbons; and the bio-remediation of air, water and soils of harmful contaminants.

Forward-Looking Statements

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Nanologix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

SOURCE NanoLogix, Inc.

NanoLogix, Inc., +1-724-346-1302
http://www.prnewswire.com

I emailed the author of that article and told her to check out NNLX.

Targets for NNLX.PK on Stocktargets.com


Ticker Entered: NNLX.PK NANOLOGIX INC
USERS CONSENSUS FORECAST FOR NNLX.PK Target Expected Return Change Since Yesterday Change Over 1 Week
Last Close: 0.2525
1 week: 0.45 78.2% 0.01 0.02
1 month: 0.58 129.7% 0 0.03
3 months: 0.84 232.6% 0.04 0.07
6 months: 1.18 367.3% 0.05 0.03
12 months: 2.27 799% 0.25 0.18

PROFESSIONAL ANALYSTS, BROKERS AND FUND
MANAGERS FORECAST FOR NNLX.PK
Enter your Pro Targets Company Target Horizon Upside Recommendation Date
Avge Pro Target 0.92 12 Months 264.3%
TTS Zurich 0.92 12 Months 264.3% Buy 03/30/06

Just hit 0.298....

MIAMI, Apr 25, 2006 (M2 PRESSWIRE via COMTEX) -- We like stocks trading big dollar value volume! A very interesting indicator to look for is where the money is flowing into. We have a filter that we watch every morning that shows us "Dollar Volume". We also like stocks that are trading at bargain prices. As of this morning, a couple of these stocks are: (OTC: GSNH), (OTC: PGDP), (OTC: GHLT), (OTC: NNLX)

Wall Street News Alert: Market Alert for Tuesday! April 25, 2006

Weston, FLA., Apr 25, 2006 (M2 PRESSWIRE via COMTEX) -- Wall Street News Alert's "stocks to watch" this morning are: Union Dental Holdings Inc (OTCBB: UDHI), NanoLogix, Inc. (OTC: NNLX), Calypte Biomedical Corporation (AMEX: HIV), China Medical Technologies, Inc. (NASDAQ: CMED) and World Heart Corporation (NASDAQ: WHRT).

From www.bellwetherreport.com

NanoLogix, Inc

NanoLogix, Inc (OTCPK:NNLX), is a company that our research team will be tracking over the ensuing weeks. They recently came out with a significant corporate development, causing a market stir. The BWR Research Team will continue to bring its subscribers cutting edge research tools, and second to none customer service.

NanoLogix, Inc a nano-biotechnology company who has an extensive portfolio of patents, this morning announced that it has engaged Sergey Gazenko PhD to join the hydrogen generation technologies team.

He will also assist in NanoLogix's commercial demonstration unit at Welch. The Welch's unit has been constructed, and Dr. Gazenko will assist in investigating its experimental parameters in order to maximize its efficiency.

Dr. Sergey Gazenko is an internationally respected Microbiologist and Molecular Biologist with more than 20 years of experience in research and various corporate research positions. His work over the years has contributed to several products developed. Dr. Gazenko studied and received his Masters at Moscow State Pedagogical Institute in New York City and received his Doctorate from The Institute of Applied Biochemistry, Moscow, Russia.

Dr. Gazenko's work will assist in the increased efficacy of NanoLogix's hydrogen generating system and determine conclusively the method in which NanoLogix's technologies interface and compliment current alternative fuel systems such as, methane production. Lab models and research will be necessary to document improvements in the overall methodologies and contribute to further patents.

NanoLogix is led by Mitchell S. Felder M.D., who has been a co-author on fifteen of NanoLogix's patents and has worked in its clinical medical efforts. Dr. Felder has assisted in the prior investment banking, publicity and marketing efforts of the Company. Dr. Felder attended the University of Pennsylvania and received a B.A. degree in sociology in 1975. He is a diplomate and member of the American Academy of Neurology. Dr. Felder then received his Doctor of Medicine (M.D.) degree from the University of Rome, Italy in 1983. Dr. Felder is a diplomate in the field of neurology. Dr. Felder is joined by David C. McClelland Sr. who serves as the Company's President and CFO. Mr. McClelland has over 15 years experience in technology and business development taking several companies through development of intellectual property to revenues in sectors such as medical, software, biotechnology, commercial products, etc. He holds a Bachelor's Degree in Mechanical Engineering of Technology from Gannon University, Erie, Pennsylvania and several degree credits from Penn State University in business, plastics and engineering.

Additionally, Mr. McClelland has ten years experience teaching manufacturing and management courses with area colleges. Mr. McClelland is an apprentice graduate of General Electric Company in 1976.
Mitchell S. Felder M.D., CEO of NanoLogix, commented, "We are very pleased to have Dr. Gazenko. NanoLogix has greatly strengthened the depth of its hydrogen bioreactor team by having such an accomplished microbiologist on board."
Following this news, NanoLogix, Inc took a bit of a dive as they traded down over 7.0% as this stock seems to be experiencing a bit of profit taking following the company’s recent run from $0.20 to $0.30 a share. The last three days have been extremely exciting as they have traded at an above average volume as this company continues to strive to help save lives. The BWR Research Team will continue to follow the market sentiment on this company and numerous others.